Brentuximab vedotin (Adcetris®) for CD30+ cutaneous T-cell lymphoma (CTCL)

Assessment Status Rapid Review complete
Drug Brentuximab vedotin
Brand Adcetris®
Indication Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (license extension).
Assessment Process
Rapid review commissioned 07/02/2018
Rapid review completed 06/03/2018
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.

The HSE has approved reimbursement following confidential price negotiations, December 2022.